2023 Fiscal Year Final Research Report

Development of Inactivation Treatment of Multidrug Resistant Bacteria in Hospital Wastewater

Research Project

PDF

Project/Area Number	20H02289
Research Category	Grant-in-Aid for Scientific Research (B)
Allocation Type	Single-year Grants
Section	一般
Review Section	Basic Section 22060:Environmental systems for civil engineering-related
Research Institution	Osaka Medical and Pharmaceutical University (2021-2023) Osaka University of Pharmaceutical Sciences (2020)
Principal Investigator	Azuma Takashi 大阪医科薬科大学, 薬学部, 助教 (10634222)
Co-Investigator(Kenkyū-buntansha)	臼井優酪農学園大学, 獣医学群, 教授 (60639540) 村上道夫大阪大学, 感染症総合教育研究拠点, 特任教授(常勤) (50509932)
Project Period (FY)	2020-04-01 – 2024-03-31
Keywords	病院排水 / 薬剤耐性菌 / 薬剤耐性菌遺伝子 / 抗菌薬 / オゾン処理 / 不活化処理 / 定量的微生物リスク評価
Outline of Final Research Achievements	To understand the current status of antimicrobial-resistant bacteria and residual antimicrobials in the aquatic environment, a survey of hospital wastewater discharged to the public sewer system, the wastewater treatment plant that treats this wastewater, and the rivers that receive the treated wastewater was conducted, followed by inactivation experiments using different wastewater treatments. The results showed that antimicrobial-resistant bacteria were detected in the hospital wastewater at a wide range of concentrations, from several CFU/mL to several thousand CFU/mL, and antimicrobials were also present at concentrations ranging from several ng/L to more than 10 μg/L. The antimicrobials were ozone-based and their concentrations ranged from several CFU/mL to several thousand CFU/mL. These contaminants can be effectively inactivated by ozone-based advanced wastewater treatment, suggesting that upgrading water treatment may be one of the effective countermeasures.
Free Research Field	環境衛生学、衛生薬学、水環境工学
Academic Significance and Societal Importance of the Research Achievements	本研究は、医療機関に由来する排水中に存在する薬剤耐性菌と残留抗菌薬の存在実態と環境への負荷影響を明らかにするとともに、環境中に流入するこれらの新たな汚染物質による環境リスクの削減又は軽減対策として、水処理の高度化の展望を明らかにしている。本研究により得られた成果は、医療先進国であることが知られている日本において意義深く、世界的に対策を行うことが喫緊の課題になっている薬剤耐性（AMR）対策アクションプランの一助となると考えられる。また、欧米等の先進国や、急速に発展を続けるアジア諸国においても同様の対策検討の発展への寄与が期待される。